The historical rank and industry rank for Silk Road Medical's Gross Margin % or its related term are showing as below:
SILK'
s Gross Margin % Range Over the Past 10 Years
Min: 64.03 Med: 71.75 Max: 74.92
Current: 73.31
During the past 7 years, the highestGross Margin % of Silk Road Medical was 74.92%. The lowest was 64.03%. And the median was 71.75%.
SILK's Gross Margin % is ranked better than 81.26% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 53.37
vs SILK: 73.31
Silk Road Medical had a gross margin of 73.62% for the quarter that ended in Dec. 2023 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Silk Road Medical was 0.50% per year.
Silk Road Medical Gross Margin % Historical Data
The historical data trend for Silk Road Medical's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Silk Road Medical's Gross Margin %
For the Medical Devices subindustry, Silk Road Medical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silk Road Medical's Gross Margin % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Silk Road Medical's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Silk Road Medical's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Silk Road Medical (NAS:SILK) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Silk Road Medical had a gross margin of 73.62% for the quarter that ended in Dec. 2023 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Silk Road Medical Gross Margin % Related Terms
Thank you for viewing the detailed overview of Silk Road Medical's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Silk Road Medical (Silk Road Medical) Business Description
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SILK has been successfully added to your 